Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
KalVista Pharmaceuticals, Inc. (KALV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/04/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets April 30, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $56,238 $30,732 Marketable securities 93,137 135,470 Research and development tax credit receivable 16,568 14,098 Prepaid expenses and other current assets 6,383 13,347 Total current assets 172,326 193,647 Property and equipment, net 2,948 2,178 Right of use assets 7,822 7,862 Other assets 106 193 Total assets $183,202 $203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $4,817 $3,638 Accrued expenses 9,128 6,961 Lease liability - current portion 1,087 977 Total current liabilities 15,032 11,576 Long-term liabilities: Lease liability - net of current portion 7,145 7,211 Total long-term liabilities 7,145 7,211stock..." |
|
| 07/07/2023 |
10-K
| Annual Report for the period ended April 30, 2023 |
| 03/10/2023 |
SC 13G
| SUVRETTA CAPITAL MANAGEMENT, LLC reports a 5.3% stake in KalVista Pharmaceuticals, Inc. |
| 03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets January 31, April 30, 2023 2022 Assets Current assets: Cash and cash equivalents $ 85,049 $ 30,732 Marketable securities 86,636 135,470 Research and development tax credit receivable 11,892 14,098 Prepaid expenses and other current assets 8,556 13,347 Total current assets 192,133 193,647 Property and equipment, net 3,037 2,178 Right of use assets 8,101 7,862 Other assets 197 193 Total assets $ 203,468 $ 203,880 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,698 $ 3,638 Accrued expenses 8,851 6,961 Lease liability - current portion 1,057 977 Total current liabilities 11,606 11,576 Long-term liabilities: Lease liability - net of current portion 7,421 7,211 Total long-term liabilities 7,421 7,..." |
|
| 02/14/2023 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 3.1% stake in Kalvista Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 9.4% stake in KalVista Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| FMR LLC reports a 5.3% stake in KALVISTA PHARMACEUTICALS INC |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
SC 13G/A
| FRANKLIN RESOURCES INC reports a 0% stake in KALVISTA PHARMACEUTICALS, INC. |
| 01/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/09/2023 |
SC 13D
| TCG Crossover GP I, LLC reports a 9.9% stake in KALVISTA PHARMACEUTICALS, INC. |
| 01/09/2023 |
SC 13G
| Venrock Healthcare Capital Partners III, L.P. reports a 8.6% stake in KalVista Pharmaceuticals, Inc. |
| 01/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.6% stake in KALVISTA PHARMACEUTICALS INC |
| 01/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/30/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/27/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 12/08/2022 |
8-K
| Quarterly results |
| 12/08/2022 |
10-Q
| Quarterly Report for the period ended October 31, 2022 |
| 10/17/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/11/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/08/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"KalVista Pharmaceuticals Reports First Fiscal Quarter Results - KVD824 Phase 2 Clinical Trial Reaches 50% Enrollment Milestone - - Open Label Extension Study Initiated for Sebetralstat - Cambridge, MA and Salisbury, England, September 8, 2022 – KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2022." |
|
| 09/08/2022 |
10-Q
| Quarterly Report for the period ended July 31, 2022 |
| 08/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/15/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/07/2022 |
8-K
| Quarterly results |
|
|
|